Adoptive T-Cell Therapy for Epstein-Barr Virus–Related Lymphomas

Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS Sandhya Sharma , BS1xSandhya SharmaSearch for articles by this author; and Cliona M. Rooney , PhD1xCliona M. RooneySearch for articles by this author Show More 1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX https://doi.org/10.1200/JCO.20.01709 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveAdoptive immunotherapy with Epstein-Barr virus (EBV)–specific T cells has been used for > 25 years to treat EBV-related lymphoma. We reviewed the experience over this time to evaluate the activity of this approach and how it has evolved.Knowledge GeneratedManufacturing improvements have simplified the preparation of donor-specific EBV-specific T cells in the post-transplant or autologous setting while maintaining the same activity as the initial more complex processes. Allogeneic banked cells also show activity and are immediately available.RelevanceAllogeneic banks of EBV-specific T cells are already a standard-of-care therapy in Europe, and a licensed product will likely become available in the United States. Current trials testing genetic modifications and combination therapies to increase potency will broaden the applicability of this strategy.SUPPORTSupported by National Cancer Institute Grants No. P50CA126752 and P01CA094237, the Stand Up To Cancer (SU2C)/American Association for Cancer Research (AACR) 604817 Meg Vosburg T-Cell Lymphoma Dream Team, and the Leukemia and Lymphoma Society. SU2C is a program of the Entertainment Industry Foundation administered by the AACR.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTAdoptive T-Cell Therapy for Epstein-Barr Virus–Related LymphomasThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Helen E. HeslopStock and Other Ownership Interests: Marker Therapeutics, AlloVirConsulting or Advisory Role: Gilead Sciences, Novartis, Kiadis Pharma, Tessa Therapeutics, Marker Therapeutics, PACT PharmaResearch Funding: Cell Medica (Inst), Tessa Therapeutics (Inst)Cliona M. RooneyLeadership: Tessa Therapeutics (I)Stock and Other Ownership Interests: Marker Therapeutics (I), Marker Therapeutics, Bluebird Bio (I), AlloVir, AlloVir (I)Consulting or Advisory Role: Tessa Therapeutics, Tessa Therapeutics (I), Allogene (I), Memgen (I), TScan Therapeutics (I)Research Funding: Tessa TherapeuticsPatents, Royalties, Other Intellectual Property: Royalties from Takeda, Allogene, and BellicumTravel, Accommodations, Expenses: Tessa Therapeutics, Tessa Therapeutics (I)No other potential conflicts of interest were reported.